1. A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent. (4th November 2015) Authors: Sharma, Padmanee; Grimm, Marc-Oliver; Galsky, Matthew D; Baron, Ari; Bracarda, Sergio; Siefker-Radtke, Arlene; Lambert, Alexandre; Azrilevich, Alex; Retz, Margitta Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent. Issue 2 (December 2015) Authors: Sharma, Padmanee; Grimm, Marc-Oliver; Galsky, Matthew; Baron, Ari; Bracarda, Sergio; Siefker-Radtke, Arlene; Lambert, Alexandre; Azrilevich, Alex; Retz, Margitta Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. (5th March 2019) Authors: Péron, Julien; Lambert, Alexandre; Munier, Stephane; Ozenne, Brice; Giai, Joris; Roy, Pascal; Dalle, Stéphane; Machingura, Abigirl; Maucort-Boulch, Delphine; Buyse, Marc Journal: Journal of the National Cancer Institute Issue: Volume 111:Number 11(2019) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Issue 3 (March 2017) Authors: Sharma, Padmanee; Retz, Margitta; Siefker-Radtke, Arlene; Baron, Ari; Necchi, Andrea; Bedke, Jens; Plimack, Elizabeth R; Vaena, Daniel; Grimm, Marc-Oliver; Bracarda, Sergio; Arranz, José Ángel; Pal, Sumanta; Ohyama, Chikara; Saci, Abdel; Qu, Xiaotao; Lambert, Alexandre; Krishnan, Suba; Azrilevich... Journal: Lancet oncology Issue: Volume 18:Issue 3(2017:Mar.) Page Start: 312 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Issue 4 (April 2015) Authors: Weber, Jeffrey S; D'Angelo, Sandra P; Minor, David; Hodi, F Stephen; Gutzmer, Ralf; Neyns, Bart; Hoeller, Christoph; Khushalani, Nikhil I; Miller, Wilson H; Lao, Christopher D; Linette, Gerald P; Thomas, Luc; Lorigan, Paul; Grossmann, Kenneth F; Hassel, Jessica C; Maio, Michele; Sznol, Mario; Asc... Journal: Lancet oncology Issue: Volume 16:Issue 4(2015:Apr.) Page Start: 375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Issue 4 (April 2015) Authors: Weber, Jeffrey S; D'Angelo, Sandra P; Minor, David; Hodi, F Stephen; Gutzmer, Ralf; Neyns, Bart; Hoeller, Christoph; Khushalani, Nikhil I; Miller, Wilson H; Lao, Christopher D; Linette, Gerald P; Thomas, Luc; Lorigan, Paul; Grossmann, Kenneth F; Hassel, Jessica C; Maio, Michele; Sznol, Mario; Asc... Journal: Lancet oncology Issue: Volume 16:Issue 4(2015:Apr.) Page Start: 375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes. (2nd November 2022) Authors: De Backer, Mickaël; Legrand, Catherine; Péron, Julien; Lambert, Alexandre; Buyse, Marc Journal: Pharmaceutical statistics Issue: Volume 22:Number 2(2023) Page Start: 284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗